This study evaluated the anti-inflammatory activity of Vipro TM in Wistar albino rats. Healthy young adult Wistar ratswere selected and divided into four groups. Each group consisted of 3 male Wistar rats. All the animals were acclimatized for five days.Rats were divided into 4 groups. Group I served as control, in groups II, III & IV, inflammation was induced by single intraperitoneal injection of LPS. Group II served as inflammation control and

This review was undertaken to synthesize data from various databases on therapeutic clinical trials conducted on COVID- 19 in order to find out the trial details and outcome of the completed trials as well as the rationale for selecting the different trial drugs. The data were obtained from articles published December 2019 to September 4, 2020. The analysis of the data has shown that Corona Virus Disease-19 (COVID-19) is the only disease for which more than 2100 clinical trials have been registered. In these trials many existing drugs like Hydroxychloroquine (HCQ), Remdesivir, Tocilizumab, Sarilumab, Lopinavir/Ritonavir, Favipiravir, Glucocorticoids, COVID-19 convalescent plasma, Mesenchymal stem cells, Interferons, Azithromycin, Ivermectin, traditional medicines and many others are being tested globally for their efficacy in COVID-19. 225 trials have been completed as of September 4, 2020 and the results are available only for a few trials. Out of these results, two have shown favorable outcome for Favipiravir, one for HCQ alone, and one for HCQ + Azithromycin and one for Meplazumab. Topline data of two trials have resulted in the emergency use authorization (EUA) for Remdesivir on May 1, 2020. The available results of NIAD, WHO’s SOLIDARITY, Gilead and RECOVERY trials have not shown the anticipated outcome. The results of the rest of the completed trials are awaited to draw conclusion regarding the definite therapy of COVID-19. The new drug development for COVID-19 is still in its preliminary stage. Identification of potential drug candidates which could selectively inhibit Severe Acute Respiratory Syndrome-Corona Virus 2 (SARS-CoV2) protease (Mpro) and SARS CoV2 S protein is in progress.

No abstract

Many clinical trials are ongoing in India to evaluate the efficacy and safety of various interventions in COVID-19. It is mandatory that the clinical trials be registered in the Clinical Trials Registry-India (CTRI) before enrollment of study participants. The present study was carried out with the objective of collecting, compiling and analyzing various types of trial data such as study design, interventions, outcomes and study sites. The clinical trial data were collected from the CTRI web portal using the key word “COVID-19” on 14 July 2020. The CTRI data output of every study registered till 14 July 2020 was stored as PDF document and the data were transcribed into a validated excel sheet based on the pre-defined methods and categories and analyzed. A total of 293 clinical studies have been registered in CTRI as on 14 July 2020. Among them, 188 (64.16%) are interventional and 105 (35.83%) are observational studies. The interventions being evaluated are modern medications including drugs and biologicals, AYUSH formulations, Nutraceuticals, Yoga and Naturopathy. Most of the interventions are already in clinical use for non-COVID indications and undergoing repurposing evaluations for COVID-19 in the clinical studies. Trials with AYUSH formulations constitute more than half of the interventional studies (51.06%) while modern medications in 31.09% of the studies. 119 trials (63.3%) of the interventional studies are randomized studies. Large numbers of trials are conducted in the states where the incidence of COVID-19 is high. 146 interventional studies out of 188 are expected to be completed within 6 months and the outcomes of these studies may provide valid information on the potential treatments in COVID-19.